Details

Autor(en) / Beteiligte

• Makkar, Raj R
• Fontana, Gregory P
• Jilaihawi, Hasan
• Kapadia, Samir
• Pichard, Augusto D
• Douglas, Pamela S
• Thourani, Vinod H
• Babaliaros, Vasilis C
• Webb, John G
• Herrmann, Howard C
• Bavaria, Joseph E
• Kodali, Susheel
• Brown, David L
• Bowers, Bruce
• Dewey, Todd M
• Svensson, Lars G
• Tuzcu, Murat
• Moses, Jeffrey W
• Williams, Matthew R
• Siegel, Robert J
• Akin, Jodi J
• Anderson, William N
• Pocock, Stuart
• Smith, Craig R
• Leon, Martin B

Titel

Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis

Ist Teil von

• The New England journal of medicine, 2012-05, Vol.366 (18), p.1696-1704

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• This article provides 2-year data on patients with inoperable aortic stenosis randomly assigned to receive standard therapy or transcatheter aortic-valve replacement (TAVR). Death rates at 2 years were higher with standard therapy, but the rate of stroke was higher with TAVR. Symptomatic aortic stenosis, if left untreated, is characterized by a high risk of death. 1 – 6 In the randomized Placement of Aortic Transcatheter Valves (PARTNER) trial, transcatheter aortic-valve replacement (TAVR), as compared with standard therapy, in patients who were not considered to be suitable candidates for surgery, decreased the rate of death at 1 year, reduced cardiac symptoms, and improved the hemodynamic performance of the valve. 2 Longer-term outcomes are essential to guide clinical practice decisions in this elderly patient population, in which many of the patients have multiple coexisting conditions. Moreover, there is a paucity of long-term data on the performance . . .